American Cancer Society Journals shared a post on LinkedIn about a recent article by Lingying Wu et al. published in CA: A Cancer Journal for Clinicians:
“A new phase 3 trial is now available to read in CA: A Cancer Journal for Clinicians!
The FZOCUS-1 trial is a randomized, double-blind, placebo-controlled phase 3 trial aiming to compare the efficacy and safety of fuzuloparib, a PARP inhibitor, plus apatinib, a vascular epithelial growth factor receptor-2 inhibitor, versus fuzuloparib monotherapy or placebo as first-line maintenance for patients with newly diagnosed, advanced ovarian cancer (OC).
To the authors’ knowledge, this study is the first to indicate that the addition of an antiangiogenic agent (in this case, apatinib) to a PARP inhibitor (in this case, fuzuloparib) does not improve progression-free survival among patients who have BRCA-mutated or homologous recombination deficiency OC.
CA is pleased to make these phase 3 trial results available OpenAccess, ensuring broad, barrier-free access to findings that may inform standards of care.”
Title: Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial
Authors: Lingying Wu, Jing Wang, Qingshui Li, Danbo Wang, Cuiying Zhang, Junying Tang, Guonan Zhang, Min Hao, Desheng Yao, Qinglei Gao, Youzhong Zhang, Ruifang An, Rutie Yin, Li Wang, Bairong Xia, Qi Zhou, Hongying Yang, Jianqing Zhu, Kui Jiang, Zhengzheng Chen, Qiang Wu, Wei Duan, Yi Huang, Hui Zhang, Shuqing Wei, Guiling Li, Yuanguang Meng, Ke Wang, Xinfeng Yang, Xianghua Huang, Lingya Pan, Jinjin Yu, Ge Lou, Yu Zhang, Huaijun Zhou, Xiaoqing Guo, Hong Yang, Xiaodong Cheng, Xiumin Li, Wuliang Wang, Hongqin Zhao, Yunxia Li, Yingjie Yang, An Lin, Wenjun Cheng, Lihong Chen, Xiaoying Xie, Wen Di, Yuanjing Hu, Mo Chen, Hongwu Wen, Liping Cai, Xiaohua Wu, Zhongqiu Lin, Quanren Wang, Xinfeng Yang, Ning Li
Read the Full Article on CA: A Cancer Journal for Clinicians!
More posts about Ovarian Cancer.